



Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



May 27, 2021

For Immediate Release

Company Name: EPS Holdings, Inc. Representative Director: Yan Hao, Chairman & CEO (Code No.: 4282, TSE First Section) Inquiries: Kazuki Sekitani, Vice President and Corporate Officer (Tel: +81-3-5684-7873)
--

**Notice Regarding Agreement with SUZUKEN Co., Ltd. on Capital Participation
in Subsidiary of EPS Holdings, Inc.**

EPS Holdings, Inc. (the “Company”) hereby announces that an agreement was reached between the Company and SUZUKEN Co., Ltd. (“SUZUKEN”) on SUZUKEN’s capital participation in EP-PharmaLine Co., Ltd (“EP-PharmaLine”), a consolidated subsidiary of the Company, on the condition that the acquisition of shares of the Company’s common stock by Shinyo K.K. through a tender offer (the “Tender Offer”) is consummated, as described in the “Notice Regarding MBO and Recommendation Application” released separately on May 27, 2021. Details are as follows.

1. Purpose of capital participation

Since the Company and SUZUKEN agreed on the capital and business partnership as released in the “Notice of Capital and Business Partnership and Disposition of Treasury Stock through Third-Party Allocation” dated September 27, 2016, the two companies have discussed the possibility of creating new added value by leveraging the management resources and knowhow of the two corporate groups with the aim of contributing to the medical service and healthcare industries.

Based on this capital and business partnership, SUZUKEN participated in the management of the Company’s business in China by taking a 35% stake in EPS EKISHIN Co., Ltd. in October 2016, and ES-Link Co., Ltd., a joint venture company related to the Company’s CSO business, was established in October 2018 (capital contribution ratio: the Company holds a 51% stake and SUZUKEN 49%). The effect of the partnership in each business field is gradually becoming apparent.

Accordingly, to further strengthen the capital and business partnership, the two companies agreed on SUZUKEN’s capital participation in EP-PharmaLine with the aim of creating new services for pharmaceutical manufacturers and healthcare industries by combining the business process outsourcing (BPO) functions in the Company’s CSO business and its medical contact center functions with the various functions held by SUZUKEN.

2. Outline of capital participation in EP-PharmaLine

For the development and deployment of joint business through BPO, etc. for pharmaceutical manufacturers and healthcare industries, SUZUKEN will make a capital investment (capital contribution ratio of 49%) in EP-PharmaLine on October 1, 2021 (plan) on the condition of the consummation of the Tender Offer.

The details of the capital participation, including the type and amount of contribution and management setup, are presently under discussion.



3. Overview of parties to capital participation

(1) Name	SUZUKEN Co., Ltd.	EP-PharmaLine Co., Ltd.
(2) Main business area	Wholesale of ethical pharmaceuticals	DI (drug information) and other call center services, related BPO services, and medical device support services
(3) Date of establishment	August 10, 1946	November 4, 1997
(4) Location	8 Higashi-katahamachi, Higashi-ku, Nagoya-shi, Aichi	3-27-12 Nishi-Ikebukuro, Toshima-ku, Tokyo
(5) Positions and names of representatives	Hiromi Miyata, President and Executive Officer Shigeru Asano, Representative Director and Executive Vice President	Junichi Nishizuka, Chairman and Representative Director Kanami Ikeda, President and Representative Director
(6) Capital	13,546 million yen	433 million yen
(7) Number of employees	15,041 (Consolidated)	1,619
(8) Major shareholders and shareholding ratio	The Master Trust Bank of Japan, Ltd. (Trust Account): 7.09% Custody Bank of Japan, Ltd. (Trust Account): 3.86% Shionogi & Co., Ltd.: 3.65% Yoshiki Bessho: 3.46%	EPS Holdings, Inc.: 100%

4. Future outlook

After the details of the subject matter are determined, if it becomes necessary to revise business forecasts and/or if any matter to be disclosed arises, such information will be immediately disclosed.